A carregar...
Publicação
Avaliação farmacoeconómica em diversas autoridades de ATS: o caso de estudo do lumacaftor/ivacaftor (orkambi)
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.36 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
O debate sobre a introdução, a utilização e o investimento em tecnologias de saúde inovadoras repete-se em todos os sistemas de saúde.
As tecnologias que se apresentam como inovadoras também se caracterizam como complexas e caras, o que associado ao contexto epidemiológico e clínico de cada sistema justifica o debate intensivo e pouco consensual em torno desta questão.
Cada sistema de saúde, procura obter de forma sistemática, transparente, imparcial e robusta, informação relacionada com o uso de uma tecnologia em saúde na sua contextualização epidemiológica, clínica e económica, ora com produção própria de relatórios de Avaliação de Tecnologias de Saúde (ATS) ora com a análise de relatórios submetidos pelos titulares das tecnologias.
Inconsistências metodológicas nos processos de ATS entre as várias agências avaliadoras levam à descredibilização do conceito e à incerteza por parte dos decisores finais.
O objetivo deste trabalho é realizar uma análise crítica de vários relatórios de avaliação farmacoeconómica produzidos por diferentes agências de ATS europeias, de forma a inferir a uniformidade deste processo e a equidade no acesso a tecnologias de saúde por parte da população europeia. Em particular, pretende-se identificar as principais causas de disparidade neste processo e, até que ponto, as mesmas impactam o resultado final da avaliação e levam a constrangimentos e discrepâncias no acesso da população às melhores alternativas terapêuticas disponíveis.
The debate on the introduction, use and investment in innovative health technologies is repeated in all health systems. The technologies that present themselves as innovative are also characterized as complex and expensive which, associated with the epidemiological and clinical context of each system, leads to an intensive and non-consensual debate on this issue. Each health system aims for systematical, transparent, impartial and robust, information related to the use of health technologies in its epidemiological, clinical and economic context, sometimes using health technology assessment reports of their own and other times with analysis evidence submitted by others. Methodological inconsistencies between HTA processes from different evaluating agencies lead to the discrediting of the concept and uncertainty on the part of the final decision makers. The objective of this work is to carry out a critical analysis of several pharmacoeconomic evaluation reports obtained by different European HTA agencies, in order to conclude on the uniformity of this process and on equity in European access to health technologies. In particular, it is intended to identify the main causes of disparity in this process and, to what extent, they impact the outcome of the assessment and lead to constraints and discrepancies in the population's access to the best available therapeutic alternatives.
The debate on the introduction, use and investment in innovative health technologies is repeated in all health systems. The technologies that present themselves as innovative are also characterized as complex and expensive which, associated with the epidemiological and clinical context of each system, leads to an intensive and non-consensual debate on this issue. Each health system aims for systematical, transparent, impartial and robust, information related to the use of health technologies in its epidemiological, clinical and economic context, sometimes using health technology assessment reports of their own and other times with analysis evidence submitted by others. Methodological inconsistencies between HTA processes from different evaluating agencies lead to the discrediting of the concept and uncertainty on the part of the final decision makers. The objective of this work is to carry out a critical analysis of several pharmacoeconomic evaluation reports obtained by different European HTA agencies, in order to conclude on the uniformity of this process and on equity in European access to health technologies. In particular, it is intended to identify the main causes of disparity in this process and, to what extent, they impact the outcome of the assessment and lead to constraints and discrepancies in the population's access to the best available therapeutic alternatives.
Descrição
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, 2020, Universidade de Lisboa, Faculdade de Farmácia.
Palavras-chave
Fibrose quística Doenças raras Avaliação de tecnologias de saúde Custo-efetividade Mestrado integrado - 2020